ClinicaliQ Trial Snapshot
- A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn’s Disease — Active Not Recruiting • Phase II / Phase III • Gastroenterology • NCT03466411.
- Guselkumab, a new antibody treatment, shows promise for reducing symptoms and inflammation in moderate-to-severe Crohn's disease.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of guselkumab in participants with Crohn's disease. Conditions: Crohn's Disease Interventions: Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Guselkumab Dose 4, Guselkumab Dose 5, Guselkumab, Ustekinumab, Placebo Lead Sponsor: Janssen Research & Development, LLC Planned Enrollment: 1409 participants